Mechanistically, CTLA-4 inhibition reduces CD4+ Treg proliferation and induces the expansion of a Th1-like CD4+ effector populations, while inhibiting PD-1 reduces T-cell exhaustion and increases CD8+ tumor infiltrating subsets (87–90). Here, CD8A is linked to neoplasm.